Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis

What Was Tested

Researchers studied Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism in this clinical trial publication.

The effect of intravenous 1 alpha-hydroxyvitamin D3 [1 alpha(OH)D3] on circulating levels of intact parathyroid hormone (PTH 1-84) and COOH-terminal immunoreactive PTH(PTH 53-84) was examined in 13 patients on chronic hemodialysis.

Blood samples were obtained 1 week before start of treatment and then at every 2nd week.

Who Took Part

According to the abstract, 13 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The methods mention a period of 300 days.

What Was Measured

The effect of intravenous 1 alpha-hydroxyvitamin D3 [1 alpha(OH)D3] on circulating levels of intact parathyroid hormone (PTH 1-84) and COOH-terminal immunoreactive PTH(PTH 53-84) was examined in 13 patients on chronic hemodialysis.

The subject headings attached to it are Calcium, Hydroxycholecalciferols, Hyperparathyroidism, Secondary, Kidney Failure, Chronic, Parathyroid Hormone, Peptide Fragments and Renal Dialysis.

What This Means in Plain Language

This is a clinical trial of Parathyroid Hormone (PTH 1-84) in 13 patients in people with hyperparathyroidism over 300 days.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1992 (American journal of nephrology), a journal based in Switzerland.

More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.